US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.54 against a street estimate of 0.45 — a beat of 20.0%.
Analysts rate Repligen Corporation a strong buy (18 buy, 4 hold, 0 sell out of 22) with an average price target of $196.70.
CONFIDENT Repligen delivered 13% organic growth in Q2, raised full-year guidance on strong momentum in proteins (+50%), analytics (+30%), and emerging biotech. Announced BioLife cell therapy acquisition. Capital equipment orders improved significantly. Q2 2026 China specifically grew >60% in first half; OEM partnership on track for early 2027 manufacturing launch. 30% of clinical trials globally in China; 40% of cell therapy activity. Analysts pressed on order conversion timing (mostly capex plant readiness), protein market growth sustainability (Olivier split ligands/resins at 8–10% vs. growth factors at low-to-mid teens), and APAC composition (China >60% growth, OEM partnership launching early 2027). Management showed high conviction on emerging biotech recovery and 2027 capital equipment recovery. 2026-07-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.56% |
| FMR Inc | 5.91% |
| United Capital Financial Advisers Inc | 4.95% |
| Vanguard Capital Management, LLC | 4.28% |
| Vanguard Portfolio Management, LLC | 4.11% |
| Maverick Capital Ltd | 3.52% |
| State Street Corp | 3.20% |
| T. Rowe Price Associates, Inc. | 3.11% |
| Document | Date |
|---|---|
| Acquisition completed · Q4 2026 HEADLINE NUMBERS • Repligen completed its acquisition of BioLife Solutions on October 6, 2026. • BioLife shareholders received, for each BioLife sha | 2026-10-06 |
| Board / officer change · Q3 2026 REPLIGEN CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • No financial metrics provided in this filing BUSINESS & SEGMENT HIGHLIGHTS • Repligen C | 2026-09-15 |
| Company announcement · Q3 2026 REPLIGEN CORPORATION 8-K SUMMARY HEADLINE NUMBERS • Acquisition Price: $11.25 cash plus 0.1442 shares of Repligen common stock per BioLife share • T | 2026-09-08 |
| Quarterly report · Q2 2026 REPLIGEN CORPORATION - 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Total Revenue (6 months): $398.4 million, up from $351.5 mil | 2026-07-29 |
| Results announced · Q3 2026 REPLIGEN CORPORATION – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $204 million, up 12% reported / 13% organic year-over-year • Si | 2026-07-28 |
| Results announced · Q3 2026 REPLIGEN ACQUISITION OF BIOLIFE SOLUTIONS – INVESTOR SUMMARY HEADLINE NUMBERS • Total enterprise value: $1.5 billion for BioLife acquisition • Deal | 2026-07-22 |
| Shareholder vote results · Q2 2026 REPLIGEN CORPORATION (RGEN) - 8-K SUMMARY HEADLINE NUMBERS • Shareholder Meeting Date: May 14, 2026 • Shares Outstanding (as of March 16, 2026): 56, | 2026-05-15 |
| Quarterly report · Q1 2026 REPLIGEN CORPORATION — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (Q1 2026): $194.3 million, up from $169.2 million in Q1 2025 (+14.9% ye | 2026-05-06 |
Readable in the app.
| Announcement | Date |
|---|---|
| BioLife merged into Repligen with cash and stock consideration for shareholders Repligen completed its acquisition of BioLife. Each BioLife share was converted into $11.25 in cash plus 0.1442 shares of Repligen common stock, with cash paid for any fractional Repligen sh | 2026-10-06 |
| Agreement and Plan of Merger entered into with subsidiary merger entities Repligen Corporation announced that the HSR (Hart-Scott-Rodino) antitrust waiting period for its acquisition of BioLife Solutions has expired as of September 3, 2026, clearing a major regula | 2026-09-08 |
| Entry into merger agreement with BioLife Solutions announced Repligen Corporation announced on July 22, 2026 that it has agreed to acquire BioLife Solutions, Inc. through a merger agreement signed on July 21, 2026. The deal involves two merger subsidi | 2026-07-22 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Repligen Corporation — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.